New Advances in Systemic Lupus Erythematosus (SLE)
A special issue of Journal of Clinical Medicine (ISSN 2077-0383). This special issue belongs to the section "Immunology & Rheumatology".
Deadline for manuscript submissions: 20 March 2026 | Viewed by 2
Special Issue Editor
Interests: systemic lupus erythematosus; autoimmunity; rheumatoid arthritis; osteoporosis; biomarker; targeted treatment
Special Issues, Collections and Topics in MDPI journals
Special Issue Information
Dear Colleagues,
Systemic lupus erythematosus (SLE) is a chronic autoimmune disease characterized by immune-mediated inflammation affecting multiple organs. Due to a wide range of clinical manifestations, early diagnosis remains challenging. Furthermore, no single biomarker is currently available to definitively establish the diagnosis, assess disease activity, or predict disease progression.
Although advances in disease control have led to improved survival over the years, patients with SLE continue to experience higher morbidity and mortality (standardized mortality ratio: 2.66). To improve the prognosis, novel and targeted therapies are actively being developed to minimize disease activity and organ damage, as well as enhance quality of life.
This Special Issue on “New Advances in Systemic Lupus Erythematosus (SLE)” is now open for submissions. We welcome your contributions focusing on recent progress in the diagnosis and treatment of SLE.
Prof. Dr. Chang-Hee Suh
Guest Editor
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Journal of Clinical Medicine is an international peer-reviewed open access semimonthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- systemic lupus erythematosus
- autoantibodies and biomarkers
- lupus nephritis
- new and novel treatments
- targeted treatment or precision medicine
- quality of life
Benefits of Publishing in a Special Issue
- Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
- Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
- Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
- External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
- Reprint: MDPI Books provides the opportunity to republish successful Special Issues in book format, both online and in print.
Further information on MDPI's Special Issue policies can be found here.
